Literature DB >> 21084124

The development of anemia of inflammation during acute myocardial infarction.

Arie Steinvil1, Shmuel Banai, Eran Leshem-Rubinow, Ori Rogowski, Amir Halkin, Gad Keren, Ariel Finkelstein, Tamar Chundadze, Shlomo Berliner, Yaron Arbel.   

Abstract

BACKGROUND: Anemia is associated with an unfavorable outcome in acute myocardial infarction (AMI). An acute phase response could contribute to the development of anemia in AMI patients.
METHODS: We have performed a cross-sectional analysis on prospectively collected data at a tertiary hospital catheterization laboratory. Multi-adjusted linear regression models were fitted for hemoglobin as the dependent variable. ANOVA tests were used to determine interactions between time cutoffs of the respective hemoglobin and the concentrations of two inflammatory proteins, namely C-reactive protein and fibrinogen. Anemia indices were analyzed in a subgroup of 138 male AMI patients for whom frozen serum samples were available.
RESULTS: Enrolled were 1017 patients (340 with unstable angina pectoris [UAP] and 677 with AMI). Correlates of hemoglobin in the AMI group included age, male gender, the inflammatory proteins, as well as time from symptom onset to angiography (r(2)=0.47; p<0.001). A significant decrease in the concentration of hemoglobin with a parallel increase in the inflammatory proteins was observed between the time cutoff from symptom onset to angiography only in the AMI group for males and females, respectively. A pattern suggestive of anemia of inflammation including higher ferritin, lower transferring, lower transferrin saturation, and lower serum iron concentrations has been observed in anemic AMI patients ( all p<0.05).
CONCLUSIONS: Inflammation-sensitive proteins are associated with lower hemoglobin concentrations in AMI patients. We therefore suggest the possibility that at least part of the hemoglobin drop in AMI prior to angiography is related to the anemia of inflammation.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084124     DOI: 10.1016/j.ijcard.2010.10.031

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Red blood cell distribution width and 3-year outcome in patients undergoing cardiac catheterization.

Authors:  Yaron Arbel; Edo Y Birati; Ariel Finkelstein; Amir Halkin; Shlomo Berliner; Ben-Zion Katz; Miri Revivo; Hila Saranga; Itzhak Herz; Gad Keren; Shmuel Banai
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

2.  Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events.

Authors:  Yaron Arbel; Shani Shenhar-Tsarfaty; Nir Waiskopf; Ariel Finkelstein; Amir Halkin; Miri Revivo; Shlomo Berliner; Itzhak Herz; Itzhak Shapira; Gad Keren; Hermona Soreq; Shmuel Banai
Journal:  Mol Med       Date:  2014-02-12       Impact factor: 6.354

3.  Perioperative Red Blood Cell Transfusion: Harmful or Beneficial to the Patient?

Authors:  Jens Meier; Markus M Müller; Patrick Lauscher; Walid Sireis; Erhard Seifried; Kai Zacharowski
Journal:  Transfus Med Hemother       Date:  2012-03-19       Impact factor: 3.747

Review 4.  Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?

Authors:  Harsh Goel; Joshua R Hirsch; Anita Deswal; Saamir A Hassan
Journal:  Curr Atheroscler Rep       Date:  2021-08-10       Impact factor: 5.113

Review 5.  Mechanisms linking red blood cell disorders and cardiovascular diseases.

Authors:  Ioana Mozos
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

6.  Associations of plasma hepcidin with mortality risk in patients with coronary artery disease.

Authors:  Xinrui Li; Ding Ding; Yuan Zhang; Dongfang Su; Min Wang; Xuechen Chen; Yan Yang; Changjiang Hong; Gang Hu; Wenhua Ling
Journal:  Oncotarget       Date:  2017-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.